21 January 2019
Visiongain has launched a new pharma report Global Cancer Immunotherapy Market Forecast 2019-2029: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centres, Clinics.
Immunotherapeutics and targeted therapies are emerging as promising treatment options for various cancer types. In the biological cancer drug category, monoclonal antibodies (mAbs) have gained significant attention in recent years due to their target specificity, high efficacy and less toxicity.
The lead analyst of the report commented "The cancer immunotherapy market remains attractive, as it is a large and growing clinical area with growing incidence of cancer cases, globally. Significant unmet need exists in the cancer market due to the rising need for more compelling clinical evidences and improved patient convenience.
In addition, increased medical education to improve clinical practice, improved care coordination between therapies and sites of care, and enhanced decision tools and practice guidelines are expected to drive future trends and innovations."
Leading companies featured in the report include Adaxic Inc., AstraZeneca, Bayer, Bristol-Myers Squibb (BMS), Eli Lilly and Co., Medtronic Plc, Merck & Co., Inc. (Merck), Novartis, Pfizer, Roche
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs.
12 February 2019
Regenerative medicine has become an area of competition between many national governments, particularly in Asia-Pacific.
07 February 2019
The market is expected to grow strongly driven by numerous trends in the overall pharmaceutical market, such as more self-administration of medicines, the development of biological drugs and biosimilars, and the increasing burden of chronic diseases such as diabetes and high cholesterol.
31 January 2019
This report ranks the world’s top 50 generic drug manufacturers according to their generic drug revenues in 2017.